SEPTEMBER 30, 2021, CLEVELAND, OH / Journey Biosciences, Inc., a biotechnology company with an innovative predictive screening technology for high risk kidney complications associated with diabetes, today announced their company launch and introduction of their flagship product, NaviDKD®.
NaviDKD analyzes blood-based predictive biomarkers to determine an individual’s risk factor for developing high risk kidney complications associated with diabetes, including diabetes-related kidney disease (DKD). Combined with Journey Biosciences' proprietary Compass™ reporting platform, NaviDKD not only proactively identifies an individual’s risk factor, but also provides actionable insights to prevent and manage complications before they occur.
"Currently, more than 34 million Americans have diabetes. 1 out of 3 will develop kidney disease," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "Most will develop complications without outward signs or symptoms. That's where Journey Biosciences and NaviDKD screening can make a difference in how we treat diabetes, changing the conversation from reactive to proactive. NaviDKD helps proactively identify those risks so people with diabetes and their healthcare team can take action now."
Available to both health care professionals and people with diabetes, NaviDKD can be requested by visiting www.journeybio.life or consulting with your healthcare professional.
About Journey Biosciences
Journey Biosciences is on a mission to improve the lives of people with diabetes through proactive, personalized care. One in three people with diabetes faces the hidden threat of kidney disease. Our flagship solution, NaviDKD®, is an innovative blood test that identifies this risk years in advance, enabling personalized preventive care for better health outcomes. By empowering early action, we aim to significantly reduce the burden of diabetes-related kidney disease on patients and healthcare systems. Discover more at journeybio.life.
For media inquiries: media@journeybio.life
